2026年10月25日 13:30 ET 发布 · 更新于 19 天前 · 2 个来源
Moderna and Merck melanoma trial data positive, but Wall Street reacted negatively
Youtube
·
原始报道
Oncologists cheered breakthrough melanoma trial data from Moderna and Merck, showing a 42% reduction in tumor recurrence, but Wall Street reacted negatively, causing both companies' shares to fall, with Moderna's stock plunging 17%.
原文